Anna Rempel
Family Medicine · Salina, KSNPI 1093162182
Payments from drug & device makers
Across 95 payments — averaging $16.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$276
- Lilly USA, LLC$268
- Amgen$248
- Novo Nordisk$162
- Takeda Pharmaceuticals U.S.A., Inc.$108
- Pfizer$101
- plus $449 from 14 others
What the payments were for
- Food & beverage$1,611100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 14 | $276 |
| Lilly USA, LLC | 18 | $268 |
| Amgen | 16 | $248 |
| Novo Nordisk | 9 | $162 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $108 |
| Pfizer | 7 | $101 |
| Novartis | 4 | $78 |
| Dexcom, Inc. | 3 | $59 |
| Boehringer Ingelheim | 2 | $45 |
| AstraZeneca | 3 | $42 |
| Biogen | 2 | $38 |
| GSK | 2 | $30 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $30 |
| Abbott | 1 | $22 |
| Exact Sciences | 1 | $22 |
| Mimedx Group, Inc. | 1 | $20 |
| Baxter Healthcare | 1 | $19 |
| Krystal Biotech Inc | 1 | $16 |
| Melinta Therapeutics, LLC | 1 | $15 |
| Ultragenyx Pharmaceutical Inc. | 1 | $12 |
How this compares
$1,611 in reported general payments places this provider in the 70th percentile of 1,469 family medicine providers in Kansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 17 | $26,455 |
| JardianceEmpagliflozin | 25 | $19,734 |
| MyrbetriqMirabegron | 11 | $4,954 |
| Fentanyl | 20 | $1,342 |
| CholestyramineCholestyramine (With Sugar) | 12 | $1,099 |
| Easy Touch Safety Pen NeedlePen Needle, Diabetic, Safety | 12 | $971 |
| Potassium Chloride | 42 | $952 |
| Gabapentin | 46 | $847 |
| Levothyroxine Sodium | 68 | $835 |
| Pregabalin | 28 | $825 |
| Calcitonin-SalmonCalcitonin,salmon,synthetic | 11 | $659 |
| Pantoprazole Sodium | 79 | $593 |
| Losartan Potassium | 87 | $566 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 14 | $512 |
| Omeprazole | 64 | $499 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $268 | $26,45517 claims |
| Boehringer IngelheimJardiance | $45 | $19,73425 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,469 family medicine providers in Kansas.
Other family medicine in Salina
- Son NguyenSalina$17K
- Terry PolingWichita$24.2M
- Richard GloverNewton$19.6M
- Daniel DickersonLenexa$13.6M
- Patrick YaoOlathe$11.7M
- Michael RauschAugusta$8.1M
- Terry KleinWichita$5.9M
- Richard EgelhofWichita$4.1M
- Thomas KleinWichita$3.4M
- Troy HoldemanNewton$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.